History
  • No items yet
midpage
Federal Trade Commission v. Vyera Pharmaceuticals, LLC
1:20-cv-00706
S.D.N.Y.
Nov 10, 2021
Read the full case

Background

  • Trial scheduled for December 14, 2021 in an antitrust action alleging Shkreli and Mulleady orchestrated a scheme at Vyera to block generic competition to the branded drug Daraprim.
  • Martin Shkreli: Vyera founder and CEO Oct 2014–Dec 2015; thereafter remained Vyera’s largest shareholder (≈43–49%) and allegedly retained operational control even after later incarceration.
  • Kevin Mulleady: Vyera managing director Oct 2014–June 2016 and served as Phoenixus (Vyera’s parent) Chairman until Nov 2020.
  • Plaintiffs seek to admit Vyera board documents, testimony of Vyera officers (including depositions and FTC investigational testimony), and written communications between employees and Shkreli/Mulleady.
  • Defendants moved to preclude statements by current/former Vyera employees; the court analyzed admissibility under business‑records rule, deposition use, co‑conspirator exception, and party‑opponent/agent statements.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Admissibility of Vyera board documents under business‑records exception (Fed. R. Evid. 803(6)) Board minutes/records are regularly kept business records and thus admissible against all defendants. Documents are hearsay or prepared for litigation and thus untrustworthy. Court: Business‑records rule may permit admission; rule favors admitting records with any probative value if foundation is shown and opponent fails to show untrustworthiness.
Use of Vyera executives’ depositions against individual defendants (Fed. R. Civ. P. 32(a)(3)) Depositions of Vyera officers may be used against Shkreli and Mulleady as adverse parties/managing agents. Defendants seek to limit or preclude use of those depositions against them. Court: Rule 32(a)(3) permits use against individual defendants if Rule 32(a)(1) requirements are met; rule is construed liberally.
Admission of employee statements as co‑conspirator statements (Fed. R. Evid. 801(d)(2)(E)) Statements made during and in furtherance of the alleged antitrust conspiracy are non‑hearsay and admissible against Shkreli and Mulleady. Defendants argue lack of conspiracy, lack of membership, or that statements were not in furtherance; also raise withdrawal defense. Court: Plaintiffs met burden to show conspiracy and defendants’ membership; admissibility of specific statements requires preponderance that each was in furtherance; withdrawal requires affirmative evidence and defendants offered none.
Admission of employee statements as agent/employee admissions (Fed. R. Evid. 801(d)(2)(D)) Investigational testimony and employee statements about matters within the scope of their duties are non‑hearsay admissions against Shkreli/Mulleady. Defendants contest scope and trustworthiness for certain witnesses (notably Retzlaff and Mithani). Court: Rule 801(d)(2)(D) applies where statements concern matters within employees’ authority; live testimony from some witnesses reduces dispute; contested investigational testimony may still be admissible depending on foundation and scope.

Key Cases Cited

  • United States v. Kaiser, 609 F.3d 556 (2d Cir. 2010) (business‑records exception favors admission when records have probative value)
  • United States v. Gupta, 747 F.3d 111 (2d Cir. 2014) (standards for admitting co‑conspirator statements under Rule 801(d)(2)(E))
  • United States v. Leslie, 658 F.3d 140 (2d Cir. 2011) (burden and standards for proving withdrawal from a conspiracy)
  • United States v. Berger, 224 F.3d 107 (2d Cir. 2000) (resignation alone does not establish withdrawal from conspiracy)
  • United States v. Lauersen, 348 F.3d 329 (2d Cir. 2003) (employee statements admissible for matters within scope of authority)
  • United States v. Rioux, 97 F.3d 648 (2d Cir. 1996) (scope‑of‑duties analysis for admissions by employees)
  • Pappas v. Middle Earth Condo. Ass'n, 963 F.2d 534 (2d Cir. 1992) (employee statements as admissions by party‑opponent)
  • United States v. Agne, 214 F.3d 47 (1st Cir. 2000) (corporate employee testimony admitted against corporate officer)
  • Klein v. Tabatchnick, 459 F. Supp. 707 (S.D.N.Y. 1978) (use of deposition of one adverse party against another)
Read the full case

Case Details

Case Name: Federal Trade Commission v. Vyera Pharmaceuticals, LLC
Court Name: District Court, S.D. New York
Date Published: Nov 10, 2021
Docket Number: 1:20-cv-00706
Court Abbreviation: S.D.N.Y.